Compare ARDX & OMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARDX | OMDA |
|---|---|---|
| Founded | 2007 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 996.8M | 1.2B |
| IPO Year | 2014 | 2025 |
| Metric | ARDX | OMDA |
|---|---|---|
| Price | $3.83 | $23.90 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 11 |
| Target Price | $15.14 | ★ $21.73 |
| AVG Volume (30 Days) | ★ 4.8M | 1.4M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 94.27 |
| EPS | N/A | ★ 0.04 |
| Revenue | $2,607,000.00 | ★ $260,210,000.00 |
| Revenue This Year | $37.75 | $24.96 |
| Revenue Next Year | $34.24 | $20.08 |
| P/E Ratio | ★ N/A | $606.75 |
| Revenue Growth | N/A | ★ 53.24 |
| 52 Week Low | $3.73 | $10.28 |
| 52 Week High | $8.40 | $26.92 |
| Indicator | ARDX | OMDA |
|---|---|---|
| Relative Strength Index (RSI) | 27.50 | 61.29 |
| Support Level | N/A | $23.42 |
| Resistance Level | $6.47 | $24.80 |
| Average True Range (ATR) | 0.14 | 0.91 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 12.33 | 48.89 |
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Omada Health Inc empowers individuals to make lasting health changes through personalized, virtual care between doctor's visits. The integrated platform of the company supports members with cardiometabolic conditions like prediabetes, diabetes, hypertension, musculoskeletal issues, and behavioral health needs. The company's specialized care tracks also assist members using GLP-1 medications. The company delivers measurable health outcomes and value for employers, health plans, health systems, and pharmacy benefit managers.